Tvardi Therapeutics to Participate in Upcoming Investor Conferences
JonesTrading C-Suite Fireside
Date:
Time:
Registration Link here
Oppenheimer 36th Annual
Format: Corporate presentation
Date:
Time:
Location: Virtual
Format: Corporate presentation
Date:
Time:
Location:
Barclays 28th Annual Global Healthcare Conference
Format: Fireside chat
Date:
Time:
Location:
The webcast of the JonesTrading fireside chat and Oppenheimer presentation will be accessible on the Tvardi Investors’ website. A replay of the webcasts will be available for approximately 90 days following the conference.
About
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting clinical trials with TTI-101 in hepatocellular carcinoma (NCT05440708) and TTI-109 in healthy volunteers. To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).
Contacts:
For Tvardi:
Tvardi Investor Relations
ir@tvardi.com
PJ Kelleher
617-430-7579
pkelleher@lifesciadvisors.com
Source: Tvardi Therapeutics